Literature DB >> 23714707

Linear regression of postevacuation serum human chorionic gonadotropin concentrations predicts postmolar gestational trophoblastic neoplasia.

Charlotte Lybol1, Fred C G J Sweep, Petronella B Ottevanger, Leon F A G Massuger, Chris M G Thomas.   

Abstract

OBJECTIVE: Currently, human chorionic gonadotropin (hCG) follow-up after evacuation of hydatidiform moles is essential to identify patients requiring chemotherapeutic treatment for gestational trophoblastic neoplasia (GTN). We propose a model based on linear regression of postevacuation serum hCG concentrations for the prediction of GTN.
METHODS: One hundred thirteen patients with at least 3 serum samples from days 7 to 28 after evacuation were selected from the Dutch Central Registry for Hydatidiform Moles (1994-2009). The slopes of the linear regression lines of the first 3 log-transformed serum hCG and free β-hCG values were calculated. Receiver operating characteristic curves were constructed to calculate areas under curve (AUCs).
RESULTS: The slope of the hCG regression line showed an AUC of 0.906 (95% confidence interval, 0.845-0.967). Gestational trophoblastic neoplasia could be predicted in 52% of patients with GTN at 97.5% specificity (cutoff, -0.020). Twenty-one percent of patients with GTN could be predicted before diagnosis according to the International Federation of Gynecology and Obstetrics 2000 criteria. The slope of free β-hCG showed an AUC of 0.844 (95% confidence interval, 0.752-0.935), 69% sensitivity at 97.5% specificity, and 38% of patients with GTN could be predicted before diagnosis according to the International Federation of Gynecology and Obstetrics criteria.
CONCLUSIONS: The slope of the linear regression line of hCG proved to be a good test to discriminate between patients who will achieve spontaneous disease remission and patients developing GTN. The slope of free β-hCG seems to be a better predictor for GTN than the slope of hCG. Although this model needs further validation for different assays, it seems a promising way to predict the more aggressive cases of GTN.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23714707     DOI: 10.1097/IGC.0b013e31829703ea

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  2 in total

1.  High Incidence of Gestational Trophoblastic Disease in a Third-Level University-Hospital, Italy: A Retrospective Cohort Study.

Authors:  Giampiero Capobianco; Elettra Tinacci; Laura Saderi; Francesco Dessole; Marco Petrillo; Massimo Madonia; Giuseppe Virdis; Alessandro Olivari; Davide Adriano Santeufemia; Antonio Cossu; Salvatore Dessole; Giovanni Sotgiu; Pier Luigi Cherchi
Journal:  Front Oncol       Date:  2021-05-05       Impact factor: 6.244

2.  Early Detection of Gestational Trophoblastic Neoplasia Based on Serial Measurement of Human Chorionic Gonadotrophin Hormone in Women with Molar Pregnancy.

Authors:  Roya Riahi; Abbas Rahimiforoushani; Keramat Nourijelyani; Nooshin Akbari Sharak; Mahmood Bakhtiyari
Journal:  Int J Prev Med       Date:  2020-12-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.